The experience with the use of the GLP-1 analog liraglutide (Victoza) for the optimization of metabolic control and correction of the body mass in the patients with type 2 diabetes mellitus

Cover Page

Abstract


The optimal control of diabetes mellitus (DM) should ensure not only the achievement and maintenance of the targeted blood glucose level but also the reduction of other cardiovascular risks. Obesity is a key risk factor of the development of type 2 diabetes mellitus (DM2) and an independent risk factor of cardiovascular complications. The agonists of glucagon-like peptide-1 (GLP-1) are currently considered to be the sole hypoglycemic agents that not only effectively correct hyperglycemia but also reduce the excessive body weight. Liraglutide (Victoza, Novo Nordisk) is the first long-acting analog of human GLP-1 approved for the application in the treatment of DM2 at the early stages of the disease in the form of both mono- and combined therapy. We present the literature review of the results of randomized clinical studies and our own experience with the use of Victoza for glycemic control and correction of the body weight in the patients presenting with type 2 diabetes mellitus.

T V Saprina

Email: tvsaprina@sibmail.com

T K Gudkova

V A Stoliarova

S Iu Martynova

N G Dudar'kova

T G Iaroshevskaia

V N Latypova

  1. IDF Diabetes Atlas, 5th Edition, 2011. http://www.idf.org/diabetesatlas/5e/the-global-burden
  2. Turner R.C., Cull C.A., Frighi V., Holman R.R. UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: prospective requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
  3. Дедов И.И., Шестакова М.В. Виктоза (лираглутид): первый аналог человеческого ГПП-1 в лечении сахарного диабета 2-го типа. Практическое руководство для врачей. М 2010; 46.
  4. Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab, 1995; 80: 952-957.
  5. Шестакова M.B., Викулова О.К. Современные возможности фармакотерапии сахарного диабета 2-го типа при помощи аналогов глюкагоноподобного пептида-1 (ГПП-1). Сахарный диабет, 2007; 1: 9-15.
  6. Holst J.J. GLP-1 receptor agonists for the treatment of diabetes. Int Diabetes Monitor 2005;17(6): 11-18.
  7. Аметов А.С. Достижение двух целей терапии: контроль гликемии и снижение массы тела. Российский медицинский журнал 2006; 17: 24 (363): 2.
  8. Garber A., Henry R., Ratner R. et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481.
  9. Marre M., Shaw J., Brändle M., Bebakar W.M., Kamaruddin N.A., Strand J., Zdravkovic M., Le Thi T.D., Colagiuri S. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycemia and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-278.
  10. Nauck M., Frid A., Hermansen K., Shah N.S., Tankova T., Mitha I.H., Zdravkovic M., Düring M., Matthews D.R. LEAD-2 Study Group Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes. Diabetes Care 2009; 32: 84-90.
  11. Russell-Jones D., Vaag A., Schmitz O., Sethi B.K., Lalic N., Antic S., Zdravkovic M., Ravn G.M., Simó R. Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia 2009; 52: 2046-2055.
  12. Sullivan S.D., Alfonso-Cristancho R., Conner C., Hammer M., Blonde L. Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. Cardiovascular Diabetology 2009; 8: 12:1-9.
  13. Zinman B., Gerich J., Buse J.B., Lewin A., Schwartz S., Raskin P., Hale P.M., Zdravkovic M., Blonde L. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1224-1230.
  14. Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol 2009; 297(1-2):137-140.
  15. Jendle J., Nauck M.A., Matthews D.R., Frid A., Hermansen K., Düring M., Zdravkovic M., Strauss B.J., Garber A.J. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009; 11(12):1163-72.

Views

Abstract - 972

Cited-By


PlumX

Dimensions


Copyright (c) 2012 Saprina T.V., Gudkova T.K., Stoliarova V.A., Martynova S.I., Dudar'kova N.G., Iaroshevskaia T.G., Latypova V.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies